Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Non-Hodgkin's Lymphoma treatment details. Biologic therapy. The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States

Survival: 24.3 months
Toxicity Grade: 4
Treatments: Biologic therapy
Country: United States
City/State/Province: Houston, Texas
Hospital: The University of Texas M. D. Anderson Cancer Center
Journal: Link
Date: 7/2012

This phase 2 study involved 38 mantle-cell lymphoma patients. The median patient age was 64 years and 92% were male.

Patients were treated with the biologic therapy agents lenalidomide and rituximab (a monoclonal antibody for CD20 that causes the immune system to attack tumor cells).

The most severe toxicities were of grade 4 and included blood clots. Grade 3 fatigue and abdominal pain, as well as grade 2 infection, were reported.

The median overall survival was 24.3 months.

This study was supported by the pharmaceutical company Celegene.

Correspondence: Dr. Michael Wang; email:

E-mail to a Friend Email Physician More Information